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Studies have shown that anti-HLA donor speciﬁc antibodies
are detrimental in solid organ transplantations. However,
their roles in hematopoietic stem cell transplantation (HSCT)
have not been fully studied. The aim of our study was to
investigate the levels of anti-HLA donor speciﬁc antibodies
(DSA) and their impact on graft outcome in HSCT.
Patients and Methods: 49 recipients of allogeneic HSCTwith
anti-HLA DSA pre-transplant were included in the study
between July, 2006 and July, 2012. All patients (pts) were
screened foranti-HLAantibodiesusingLABScreenPRAand/or
LABScreen Mixed kits. And antibody speciﬁcity analysis was
conducted for screening positive patients using LABScreen
Single Antigen beads on Luminex platform method (One
Lambda Inc., CanogaPark, CA). Resultswere expressed asmean
ﬂuorescence intensity (MFI) with MFI  500 considered posi-
tive. Sera from initial testing and the time of transplant (Tx) for
each patient were included in the analysis. Pretransplant
specimens with the highest MFI were used in the analysis.
Results:Majority of pts who had anti-HLA DSAwere females
(91.8%). The transplant donors included in three categories:
16 haplo-identical, 12 double umbilical cord blood units
(DCBU), and 21 unrelated donors. More class II DSAs (67%)
were observed than class I (33%). HLA-DPB1 only DSA
accounted for 48.8%. Forty-three of the 49 patients had DSA
at the time of Txt. Of the 43 pts, 27 had DSA <5,000 MFI, 10
had DSA >5,000 MFI, and 6 had DSA >10,000 MFI. Early
death occurred in 4 pts (3 had DSA <5,000 MFI, 1 had DSA
>5,000 MFI). Seven pts developed rejection/primary GF, 6
pts had secondary GF within 100 days of transplantation and
9 pts had mixed chimerism. Of the 7 pts with rejection/
primary GF, 3 were haplo-identical Tx (all DSA >5,000 MFI)
and 4 were unrelated (2 with DSA <5,000 MFI and 2 with
DSA >5,000 MFI). The rate of rejection/primary GF was
higher in pts who had DSA >5,000 MFI (5/15) compared to
those DSA <5,000 MFI (2/24) (P ¼ .0846). While in contrast,
more pts with secondary GF within 100 days (5/6) or mixed
chimerism (8/9) had DSA <5,000 MFI (P ¼ .3461, P ¼ .21,
respectively). Of the 6 pts with secondary GF, 1 had haplo-
identical Tx (DSA <5,000 MFI), 2 unrelated (DSA <5,000
MFI), and 3 DCBU (1 DSA >5,000 MFI, 2 DSA <5,000 MFI).
Conclusion: At least moderate DSA (MFI >5,000) seemed
more frequently to result in rejection/primary graft failure
while secondary GF/mixed chimerism could be associated
more with lower DSA levels (MFI<5,000) suggesting that DSA
could be a predisposing factor for these to develop in the
appropriate setting (e.g. reduced-intensity conditioning). Over
half of the pts with rejection/primary or secondary GF hadDSA
toHLA-DPB1only (7/13). This suggested thatmatching atDPB1
locuscouldbeas importantasmatching inotherHLAloci. These
results suggest that avoidance of DSA evenwith lowMFI levels
could be essential for improving graft outcome in HSCT pts.470
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Background: While CB transplantation (CBT) recipients are
at signiﬁcant risk for CMV infection, the course of this
infection after CBT is not well understood.
Methods: We examined the incidence, nature, risk factors &
outcomes of CMV infection in 154 double-unit CBT recipients
transplanted between 10/2005 & 5/2012. Patients received
low dose acyclovir as prophylaxis & were monitored for CMV
reactivation in the blood by antigenemia assay or qPCR. End-
organ disease was diagnosed by standard criteria. Addition-
ally, patients with severe pulmonary compromise in the
setting of viremia not fulﬁlling criteria for CMV pneumonia
were deﬁned as CMV pulmonary syndrome.
Results: 154 patients [median age 41 years (range 0.9-69),
median weight 67 kg (range 8-125), 83 (54%) CMV seropos-
itive] were transplanted for hematological malignancies with
myeloablative (n ¼ 118, 77%) or non-myeloablative (n ¼ 36,
23%) conditioning & calcineurin-inhibitor/mycophenolate
mofetil immunosuppression. No patient received anti-
thymocyte globulin. CB grafts were 4-6/6 HLA-A,B antigen,
-DRB1 allele matched to the recipient. CMV reactivation was
restricted to CMV seropositive patients. Of CMV+ CBT recip-
ients monitored by antigenemia (n ¼ 56), 37 (66%) patients
reactivated (median onset 40 days, range -1-294). Of these,
7/37 (19%) developed diseasewith their initial reactivation: 1
pneumonia (onset 58 days), 1 pulmonary syndrome (onset
39 days), & 5 gastrointestinal (GI) disease (median onset 54
days, range 49-67). Notably, all 27 CMV+ patients monitored
by PCR reactivated at a median of 33 days (range 3-64). Of
these, 4/27 (15%) patients developed CMV disease (1 pneu-
monia & 3 pulmonary syndrome) at a median of 38 days
(range 10-56). None had GI disease with their initial infec-
tion. In Cox regression analysis including patient age, diag-
nosis, conditioning intensity, engrafting unit infused CD34+
dose & engrafting unit-recipient HLA-match, no factor was
associated with the risk of severe initial CMV infection
(disease or pulmonary syndrome). Recurrent infection has
been observed in 29 patients, to date, with reactivation
occurring in the context of GVHD and its therapy in 19/29
(66%) patients. With a median 34 months (range 5-79)
follow-up of CMV+ patients, CMV infection has caused (n¼ 2,
both pneumonia) or contributed (n ¼ 7) to death in a total of
9 of the 83 (11%) CMV+ patients, with 7/9 deaths occurring
with the initial CMV infection.
Conclusions: CMV infection remains a major cause of
morbidity & mortality in seropositive CBT recipients. PCR
surveillance permits earlier detection of reactivation but
whether this improves the clinical outcome requires further
investigation. CMV-associated lung disease, in particular,
